More tools:Markets·Screener·Research·Chat

Instil Bio, Inc. Common Stock (TIL) Financial Statements

Instil Bio, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00ZGYN5X7
XNAS · usd
7.82▲ 0.24 (3.17%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales—
EV / Revenue—
EV / EBITDA
Financial Highlights
Revenue (TTM)—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close7.58
Day's Range7.50 – 7.82
52-Week Range5.66 – 30.50
Volume6,280
Avg Volume7,449
Share Statistics
Shares Outstanding
Employees17
ExchangeXNAS
Listed2021-03-19
Share count as of August 11, 2026
Loading Income Statement…
Key questions about Instil Bio, Inc. Common Stock (TIL)
What is Instil Bio, Inc. Common Stock's Market Cap?
Instil Bio, Inc. Common Stock's Market Cap is $53.0M, based on as-reported figures from SEC (XBRL) filings.
What is Instil Bio, Inc. Common Stock's Enterprise Value?
Instil Bio, Inc. Common Stock's Enterprise Value is $47.5M, based on as-reported figures from SEC (XBRL) filings.
What is Instil Bio, Inc. Common Stock's EV / EBITDA?
Instil Bio, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Instil Bio, Inc. Common Stock's Net Income (TTM)?
Instil Bio, Inc. Common Stock's Net Income (TTM) is -$30.3M, based on as-reported figures from SEC (XBRL) filings.
What is Instil Bio, Inc. Common Stock's EBITDA?
Instil Bio, Inc. Common Stock's EBITDA is -$36.9M, based on as-reported figures from SEC (XBRL) filings.
What is Instil Bio, Inc. Common Stock's Diluted EPS (TTM)?
Instil Bio, Inc. Common Stock's Diluted EPS (TTM) is -4.46, based on as-reported figures from SEC (XBRL) filings.
What is Instil Bio, Inc. Common Stock's Net Debt?
Instil Bio, Inc. Common Stock's Net Debt is -$5.5M, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
In-process research and development—
Research and development
General and administrative
Restructuring and impairment charges, net
Total operating expenses
Loss from operations
Interest income
Interest expense
Other rental income
Gain on contract termination——
Other (expense) income, net——
Net loss
Basic (in dollars per share)
Diluted (in dollars per share)